Diagnostic value of lymphopaenia and elevated serum ACE in patients with uveitis.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
10 2021
Historique:
received: 15 04 2020
revised: 22 07 2020
accepted: 17 08 2020
pubmed: 13 9 2020
medline: 3 3 2022
entrez: 12 9 2020
Statut: ppublish

Résumé

To evaluate the diagnostic worth of elevated serum ACE (sACE) and lymphopaenia, singly or combined, in diagnosing sarcoid uveitis. Monocentric retrospective study, on a cohort of 996 adult patients referred to our department between March 2001 and December 2018 for a diagnostic work-up of uveitis. The sensitivity (SE), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) of the two biomarkers were calculated in different contexts. Eight hundred and sixty-eight patient cases were reviewed. The mean age at uveitis onset was 49.4 (±18.6) years. Of them, 144 patients had a diagnosis of sarcoid uveitis. An elevated sACE had SE of 45.8%, Sp of 88.8%, PPV of 44.9% and NPV of 89.2% in diagnosing sarcoid uveitis. For lymphopaenia, SE was 15.3%, Sp was 96.7%, PPV was 47.8% and NPV was 85.2%. For the combination of elevated sACE and lymphopaenia, SE was 18.9%, Sp was 99.0%, PPV was 73.9% and NPV was 89.5%. The value of this combination varied according to patient age at diagnosis plus anatomoclinical entities: for patients aged ≤50 years, SE was 31.3%, Sp was 99.7%, PPV was 90.9% and NPV was 94.3%. For granulomatous uveitis, SE was 26.2%, Sp was 97.3%, PPV was 73.3% and NPV was 82.5%. A combination of elevated serum ACE and lymphopaenia more convincingly suggests sarcoid uveitis than these investigational tests used alone, especially in patients with granulomatous uveitis, while a lack of these markers corresponds to a high NPV. NCT03863782.

Identifiants

pubmed: 32917626
pii: bjophthalmol-2020-316563
doi: 10.1136/bjophthalmol-2020-316563
pmc: PMC8479750
doi:

Substances chimiques

Peptidyl-Dipeptidase A EC 3.4.15.1

Banques de données

ClinicalTrials.gov
['NCT03863782']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1399-1404

Informations de copyright

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Am J Ophthalmol. 2005 Sep;140(3):509-16
pubmed: 16196117
Am J Ophthalmol. 2002 Apr;133(4):499-505
pubmed: 11931783
Am J Ophthalmol. 2016 Oct;170:161-167
pubmed: 27521608
Br J Ophthalmol. 2019 Oct;103(10):1418-1422
pubmed: 30798264
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Am J Ophthalmol. 2001 May;131(5):647-52
pubmed: 11336942
Am J Ophthalmol. 2019 May;201:89
pubmed: 30739719
Am J Ophthalmol. 2006 Jan;141(1):185-7
pubmed: 16386995
Autoimmun Rev. 2014 Aug;13(8):840-9
pubmed: 24704868
Medicine (Baltimore). 2001 Jul;80(4):263-70
pubmed: 11470987
Lancet. 1990 May 5;335(8697):1078-80
pubmed: 1970380
Br J Ophthalmol. 2010 Feb;94(2):219-22
pubmed: 19713200
Autoimmun Rev. 2017 May;16(5):504-511
pubmed: 28279837
Med Decis Making. 1984;4(2):137-50
pubmed: 6472062
Autoimmun Rev. 2017 Dec;16(12):1254-1264
pubmed: 29037906
Am J Ophthalmol. 1987 Sep 15;104(3):211-7
pubmed: 2820230
Arch Ophthalmol. 2011 Apr;129(4):409-13
pubmed: 21482866
Ann Rheum Dis. 2009 Jun;68(6):777-83
pubmed: 19297344
Am J Ophthalmol. 2017 Jun;178:176-185
pubmed: 28366648
Arthritis Rheum. 2004 Dec 15;51(6):974-82
pubmed: 15593175
Ann Rheum Dis. 2011 Jan;70(1):25-31
pubmed: 21109520
Br J Ophthalmol. 2019 Sep;103(9):1296-1300
pubmed: 30442816
Br J Ophthalmol. 2016 Oct;100(10):1393-6
pubmed: 26729767
Am J Ophthalmol. 2019 Oct;206:149-153
pubmed: 31009595
Surv Ophthalmol. 2007 Nov-Dec;52(6):561-87
pubmed: 18029267
Br J Ophthalmol. 1996 Sep;80(9):844-8
pubmed: 8962842
PLoS One. 2010 Feb 05;5(2):e9088
pubmed: 20140091
BMC Ophthalmol. 2016 Feb 16;16:19
pubmed: 26879979
Autoimmun Rev. 2018 Apr;17(4):331-343
pubmed: 29427823
Ophthalmology. 2018 Jan;125(1):119-126
pubmed: 28823384
Orphanet J Rare Dis. 2012 Aug 29;7:57
pubmed: 22932001
Lancet. 2014 Mar 29;383(9923):1155-67
pubmed: 24090799

Auteurs

Philippine Cotte (P)

Ophtalmologie, Hôpital de la Croix-Rousse, Lyon, France.

Pierre Pradat (P)

Centre for Clinical Research, Hôpital De La Croix-Rousse, Lyon, France.

Laurent Kodjikian (L)

Ophtalmologie, Hôpital de la Croix-Rousse, Lyon, France.

Yvan Jamilloux (Y)

Internal Medicine, Hôpital de la Croix-Rousse, Lyon, France.

Pascal Seve (P)

Internal Medicine, Hôpital de la Croix-Rousse, Lyon, France pascal.seve@chu-lyon.fr.
Hospices Civils de Lyon, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH